Navigation Links
Target of diabetes type 1 identified,,

Researchers have identified a set of cells in the pancreas that are targeted by the white blood cells// and cause diabetes type 1.

The researchers from University of Colorado at Denver and Health Sciences Center says their research is likely to change the study of diabetes autoimmunity and may also change the way other autoimmune diseases are studied.

Diabetes type 1 is a metabolic disorder that happens due to rising levels of sugar in the blood, and mostly is due to defects in insulin secretion, insulin function or both. Type 1 diabetes is caused when specific cells that produce insulin in the pancreas are destroyed.

Previously it was thought that these cells might be of different varieties that exist at different locations in the pancreas. The new research suggests that these cells that gets destroyed are nothing but parts of the insulin itself, a peptide called B:9-23. The new concept of single target leads to possibilities that targeting this single peptide should cause the diabetes to be under control.

The research also brings to light the importance of insulin in the study of diabetes, and that of the insulin gene in causing diabetes across the generations.

The study is published in the current edition of journal Nature.

Reference: University of Colorado at Denver and Health Sciences Center, news release, May 2005
'"/>




Page: 1

Related medicine news :

1. Target for obesity treatment
2. Gel Offers A More Targeted Approach
3. In Search Of A New Drug To Target Cholesterol
4. In Search Of A New Drug To Target Cholesterol
5. Gene Target For Tuberculosis Identified
6. New Vaccine Targeted At Effective Treatment Against Tuberculosis
7. Novel Technique For Targeting Small-Cell Lung Cancer
8. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
9. Doctors, Pharma Companies Targeted By CBI Raids
10. Research Targets treatment for dementia and brain injuries
11. Cancer Treatments Fall Short Of Targets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2017)... ... 2017 , ... The Centers for Advanced Orthopaedics (The Centers), ... Robinson as chief operating officer (COO). In this role, Robinson brings more than ... of simplifying business processes and developing growth strategies to increase market share. ...
(Date:6/26/2017)... RU (PRWEB) , ... June 26, 2017 , ... ... released a whitepaper that pledges to solve many catastrophic issues within funding campaigns. ... 2017. , The typical notion of crowdfunding - the raising of funds through the ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/24/2017)... PA (PRWEB) , ... June 24, 2017 , ... ... held in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center ... evidence based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, ...
(Date:6/23/2017)... Alexandria, VA (PRWEB) , ... June 23, 2017 ... ... short of what is needed and will ultimately do significant harm to people ... care to everyone. , "While it leaves in place the Affordable Care ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... DUBLIN , June 7, 2017 Endo ... on June 7, 2017, the Hon. Joseph R. ... District of West Virginia , entered ... Systems, Inc. Pelvic Repair System Products Liability Litigation (the ... filed MDL cases to provide expert disclosures on specific ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
Breaking Medicine Technology: